Completed PHASE1 INTERVENTIONAL NCT00033202

This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor

Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.

Sponsor: Dana-Farber Cancer Institute

Updated 5 times since 2017 Last updated: Jun 2, 2009 Started: Mar 31, 2002 Completion: Feb 28, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Solid Malignancies, this trial is completed. The trial is conducted by Dana-Farber Cancer Institute and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dana-Farber Cancer Institute
Rhode Island Hospital
Sigma-Tau Research, Inc.

Data source: Sigma-Tau Research, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Providence, United States